Registro:

Referencias:

• Swearingen, B., Biller, B.M.K., Barker II, F.G., Katznelson, L., Grinspoon, S., Klibanski, A., Zervas, N.T., Long-term mortality after transsphenoidal surgery for Cushing disease (1999) Annals of Internal Medicine, 130 (10), pp. 821-824
• Morris, D., Grossman, A., The medical management of Cushing's syndrome (2002) Annals of the New York Academy of Sciences, 970, pp. 119-133
• Pereira, A.M., Van Aken, M.O., Van Dulken, H., Schutte, P.J., Biermasz, N.R., Smit, J.W.A., Roelfsema, F., Romijn, J.A., Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease (2003) Journal of Clinical Endocrinology and Metabolism, 88 (12), pp. 5858-5864. , DOI 10.1210/jc.2003-030751
• Dahia, P.L.M., Grossman, A.B., The molecular pathogenesis of corticotroph tumors (1999) Endocrine Reviews, 20 (2), pp. 136-155. , DOI 10.1210/er.20.2.136
• Lamberts, S.W.J., Glucocorticoid receptors and Cushing's disease (2002) Molecular and Cellular Endocrinology, 197 (1-2), pp. 69-72. , DOI 10.1016/S0303-7207(02)00280-0, PII S0303720702002800
• Melmed, S., Mechanisms for pituitary tumorigenesis: The plastic pituitary (2003) Journal of Clinical Investigation, 112 (11), pp. 1603-1618. , DOI 10.1172/JCI200320401
• Giacomini, D., Paez-Pereda, M., Theodoropoulou, M., Labeur, M., Refojo, D., Gerez, J., Chervin, A., Arzt, E., Bone morphogenetic protein-4 inhibits corticotroph tumor cells: Involvement in the retinoic acid inhibitory action (2006) Endocrinology, 147 (1), pp. 247-256. , http://endo.endojournals.org/cgi/reprint/147/1/247, DOI 10.1210/en.2005-0958
• Levesque, D., Rouillard, C., Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation (2007) Trends in Neurosciences, 30 (1), pp. 22-30. , DOI 10.1016/j.tins.2006.11.006, PII S0166223606002700
• Teshima, T., Hara, Y., Takekoshi, S., Teramoto, A., Osamura, R.Y., Tagawa, M., Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease (2009) Domest Anim Endocrinol, 36, pp. 3-12
• Labeur, M., Arzt, E., Stalla, G.K., Pez-Pereda, M., New perspectives in the treatment of cushing's syndrome (2004) Current Drug Targets: Immune, Endocrine and Metabolic Disorders, 4 (4), pp. 335-342. , DOI 10.2174/1568008043339703
• Paez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, G.K., Retinoic acid prevents experimental Cushing syndrome (2001) Journal of Clinical Investigation, 108 (8), pp. 1123-1131. , DOI 10.1172/JCI200111098
• Castillo, V., Giacomini, D., Paez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Holsboer, F., Arzt, E., Retinoic acid as a novel medical therapy for Cushing's disease in dogs (2006) Endocrinology, 147 (9), pp. 4438-4444. , http://endo.endojournals.org/cgi/reprint/147/9/4438, DOI 10.1210/en.2006-0414
• Pivonello, R., Ferone, D., De Herder, W.W., Kros, J.M., Del Basso De Caro, M.L., Arvigo, M., Annunziato, L., Lamberts, S.W.J., Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors (2004) Journal of Clinical Endocrinology and Metabolism, 89 (5), pp. 2452-2462. , DOI 10.1210/jc.2003-030837
• Hofland, L.J., Lamberts, S.W.J., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrine Reviews, 24 (1), pp. 28-47. , DOI 10.1210/er.2000-0001
• Van Der Hoek, J., Waaijers, M., Van Koetsveld, P.M., Sprij-Mooij, D., Feelders, R.A., Schmid, H.A., Schoeffter, P., Hofland, L.J., Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells (2005) American Journal of Physiology - Endocrinology and Metabolism, 289 (2), pp. E278-E287. , DOI 10.1152/ajpendo.00004.2005
• Batista, D.L., Zhang, X., Gejman, R., Ansell, P.J., Zhou, Y., Johnson, S.A., Swearingen, B., Klibanski, A., The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas (2006) Journal of Clinical Endocrinology and Metabolism, 91 (11), pp. 4482-4488. , http://jcem.endojournals.org/cgi/reprint/91/11/4482, DOI 10.1210/jc.2006-1245
• Colao, A., Lombardi, G., Annunziato, L., Cabergoline (2000) Expert Opin Pharmacother, 1, pp. 555-574
• Shraga-Slutzky, I., Shimon, I., Weinshtein, R., Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment (2006) Pituitary, 9 (2), pp. 151-154. , DOI 10.1007/s11102-006-9290-4
• Castillo, V.A., Gomez, N.V., Lalia, J.C., Cabrera Blatter, M.F., Garcia, J.D., Cushing's disease in dogs: Cabergoline treatment (2008) Research in Veterinary Science, 85 (1), pp. 26-34. , DOI 10.1016/j.rvsc.2007.08.009, PII S0034528807001920
• Ambrosi, B., Bochicchio, D., Fadin, C., Colombo, P., Faglia, G., Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion (1990) Journal of Endocrinological Investigation, 13 (3), pp. 257-261
• Stalla, G.K., Brockmeier, S.J., Renner, U., Newton, C., Buchfelder, M., Stalla, J., Muller, O.A., Octreotide exerts different effects in vivo and in vitro in Cushing's disease (1994) European Journal of Endocrinology, 130 (2), pp. 125-131
• Hofland, L.J., Van Der Hoek, J., Van Koetsveld, P.M., De Herder, W.W., Waaijers, M., Sprij-Mooij, D., Bruns, C., Lamberts, S.W.J., The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro (2004) Journal of Clinical Endocrinology and Metabolism, 89 (4), pp. 1577-1585. , DOI 10.1210/jc.2003-031344
• Hofland, L.J., Van Der Hoek, J., Feelders, R., Van Aken, M.O., Van Koetsveld, P.M., Waaijers, M., Sprij-Mooij, D., Lamberts, S.W.J., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 (2005) European Journal of Endocrinology, 152 (4), pp. 645-654. , DOI 10.1530/eje.1.01876
• De Bruin, C., Hanson, J.M., Meij, B.P., Kooistra, H.S., Waaijers, A.M., Uitterlinden, P., Lamberts, S.W., Hofland, L.J., Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing's disease (2008) Endocrinology, 149, pp. 4357-4366
• Schmid, H.A., Pasireotide (SOM230): Development, mechanism of action and potential applications (2008) Molecular and Cellular Endocrinology, 286 (1-2), pp. 69-74. , DOI 10.1016/j.mce.2007.09.006, PII S0303720707003449
• Robben, J.H., Van Den Brom, W.E., Mol, J.A., Van Haeften, T.W., Rijnberk, A., Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma (2006) Research in Veterinary Science, 80 (1), pp. 25-32. , DOI 10.1016/j.rvsc.2005.03.005, PII S0034528805000597
• Willeberg, P., Priester, W.A., Epidemiological aspects of clinical hyperadrenocorticism in dogs (canine Cushing's syndrome) (1982) J Am Anim Hosp Assoc, 18, pp. 717-724
• Gallelli, M.F., Cabrera Blatter, M.F., Castillo, V., A comparative study by age and gender of the pituitary adenoma and ACTH and α -MSH secretion in dogs with pituitary-dependent hyperadrenocorticism (2010) Res Vet Sci, 88, pp. 33-40
• Weckbecker, G., Briner, U., Lewis, I., Bruns, C., SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs (2002) Endocrinology, 143 (10), pp. 4123-4130. , DOI 10.1210/en.2002-220219
• Meric, S., (1995) Textbook of Veterinary Internal Medicine, , ed 4. Philadelphia, Saunders
• Ling, G.V., Stabenfeldt, G.H., Comer, K.M., Canine hyperadrenocorticism: Pretreatment clinical and laboratory evaluation of 117 cases (1979) Journal of the American Veterinary Medical Association, 174 (11), pp. 1211-1215
• Theodoropoulou, M., Zhang, J., Laupheimer, S., Paez-Pereda, M., Erneux, C., Florio, T., Pagotto, U., Stalla, G.K., Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression (2006) Cancer Research, 66 (3), pp. 1576-1582. , DOI 10.1158/0008-5472.CAN-05-1189
• Engstrom, M., Savola, J.-M., Wurster, S., Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses (2006) Journal of Pharmacology and Experimental Therapeutics, 316 (3), pp. 1262-1268. , http://jpet.aspetjournals.org/cgi/reprint/316/3/1262, DOI 10.1124/jpet.105.094128
• Holliday, N.D., Tough, I.R., Cox, H.M., A functional comparison of recombinant and native somatostatin sst 2 receptor variants in epithelia (2007) British Journal of Pharmacology, 152 (1), pp. 132-140. , DOI 10.1038/sj.bjp.0707365, PII 0707365
• Bosje, J.T., Rijnberk, A., Mol, J.A., Voorhout, G., Kooistra, H.S., Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism (2002) Domestic Animal Endocrinology, 22 (4), pp. 201-210. , DOI 10.1016/S0739-7240(02)00128-5, PII S0739724002001285
• Kooistra, H.S., Voorhout, G., Mol, J.A., Rijnberk, A., Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism (1997) Journal of Endocrinology, 152 (3), pp. 387-394
• Strowski, M.Z., Dashkevicz, M.P., Parmar, R.M., Wilkinson, H., Kohler, M., Schaeffer, J.M., Blake, A.D., Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells (2002) Neuroendocrinology, 75 (6), pp. 339-346. , DOI 10.1159/000059430
• Therrien, M., Drouin, J., Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements (1991) Molecular and Cellular Biology, 11 (7), pp. 3492-3503
• Kovalovsky, D., Refojo, D., Liberman, A.C., Hochbaum, D., Pereda, M.P., Coso, O.A., Stalla, G.K., Arzt, E., Activation and induction of Nur77/Nurr1 in corticotrophs by CRH/cAMP: Involvement of calcium, protein kinase a, and MAPK pathways (2002) Molecular Endocrinology, 16 (7), pp. 1638-1651. , DOI 10.1210/me.16.7.1638
• Tsukamoto, N., Otsuka, F., Miyoshi, T., Yamanaka, R., Inagaki, K., Yamashita, M., Otani, H., Makino, H., Effects of bone morphogenetic protein on adrenocorticotropin production by pituitary corticotrope cells: Involvement of up-regulation of bmp receptor signaling by somatostatin analogs (2010) Endocrinology, 151, pp. 1129-1141
• Paez-Pereda, M., Giacomini, D., Refojo, D., Nagashima, A.C., Hopfner, U., Grubler, Y., Chervin, A., Arzt, E., Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (3), pp. 1034-1039. , DOI 10.1073/pnas.0237312100
• Giacomini, D., Acuna, M., Gerez, J., Nagashima, A.C., Silberstein, S., Paez-Pereda, M., Labeur, M., Arzt, E., Pituitary action of cytokines: Focus on BMP-4 and gp130 family (2007) Neuroendocrinology, 85 (2), pp. 94-100. , DOI 10.1159/000100428
• Karl, M., Von Wichert, G., Kempter, E., Katz, D.A., Reincke, M., Monig, H., Ali, I.U., Schulte, H.M., Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene (1996) Journal of Clinical Endocrinology and Metabolism, 81 (1), pp. 124-129. , DOI 10.1210/jc.81.1.124
• Hira, Y., Sakai, Y., Matsushima, S., Effects of photoperiod and melatonin on the development of growth hormone cells and the pituitary-adrenal axis in the Djungarian hamster, Phodopus sungorus (2001) Archives of Histology and Cytology, 64 (2), pp. 211-222
• Filippa, V., Mohamed, F., ACTH cells of pituitary pars distalis of viscacha (Lagostomus maximus maximus): Immunohistochemical study in relation to season, sex, and growth (2006) General and Comparative Endocrinology, 146 (3), pp. 217-225. , DOI 10.1016/j.ygcen.2005.11.012, PII S0016648005003667
• Florio, T., Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases (2008) Molecular and Cellular Endocrinology, 286 (1-2), pp. 40-48. , DOI 10.1016/j.mce.2007.08.012, PII S0303720707003322
• Srikant, C.B., Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells (1995) Biochem Biophys Res Commun, 209, pp. 400-406
• Guillermet, J., Saint-Laurent, N., Rochaix, P., Cuvillier, O., Levade, T., Schally, A.V., Pradayrol, L., Bousquet, C., Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (1), pp. 155-160. , DOI 10.1073/pnas.0136771100
• Gore, A.C., Attardi, B., DeFranco, D.B., Glucocorticoid repression of the reproductive axis: Effects on GnRH and gonadotropin subunit mRNA levels (2006) Molecular and Cellular Endocrinology, 256 (1-2), pp. 40-48. , DOI 10.1016/j.mce.2006.06.002, PII S0303720706002991
• Florio, T., Arena, S., Thellung, S., Iuliano, R., Corsaro, A., Massa, A., Pattarozzi, A., Schettini, G., The activation of the phosphotyrosine phosphatase η (r-PTPη/) is responsible for the somatostatin inhibition of PC CI3 thyroid cell proliferation (2001) Molecular Endocrinology, 15 (10), pp. 1838-1852. , DOI 10.1210/me.15.10.1838
• Held-Feindt, J., Forstreuter, F., Pufe, T., Mentlein, R., Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells (2001) Molecular Brain Research, 87 (1), pp. 12-21. , DOI 10.1016/S0169-328X(00)00225-4, PII S0169328X00002254
• Hess, R.S., Saunders, H.M., Van Winkle, T.J., Ward, C.R., Concurrent disorders in dogs with diabetes mellitus: 221 cases (1993-1998) (2000) J Am Vet Med Assoc, 217, pp. 1166-1173

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------